Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

David Stephen Shulman, M.D.

Title
Institution
Department
Address

Biography
Harvard Medical School, Boston, MAMD06/2013Medicine
Boston Combined Residency in Pediatrics, Boston, MA06/2014Internship
Boston Combined Residency in Pediatrics, Boston, MA06/2016Residency
Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA06/2019Fellowship (Pediatric Hematology/Oncology)

Mentoring
Available: 03/01/21, Expires: 09/30/21

The development of CNS metastases is a devastating event for patients with relapsed sarcoma. In our practice, we have anecdotally noted increased numbers of patients who have developed CNS metastatic disease in recent years. Our hypothesis is that with the increasing use of targeted therapies for patients with relapsed sarcomas, the CNS has become a sanctuary site of relapse and the incidence of CNS relapse has increased. We aim to leverage an existing database we have developed that includes patients with solid tumors who have received targeted therapies in attempt to better understand the development of CNS metastases in patients with sarcoma. The proposed project will fall under the experimental therapeutics program at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. We have a research program focused on novel therapies for children with relapsed cancer. Our program carries out a series of ancillary clinical research projects to better understand the landscape of novel targeted therapies as well as the clinical behavior of children with relapsed solid tumors. The proposed project would be expected to be driven by a student under the mentorship of Dr. Shulman. The student should expect to participate in completion of the project design, curate existing data and collect new data, analyze the data under the mentorship of Dr. Shulman, and draft a first author manuscript. This project will involve training in clinical research in pediatric oncology, study design, manuscript preparation, and could involve shadowing in the care of children with advanced solid tumors.


Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. 5KL2TR002542-03 (David Shulman) Oct 1, 2020 - Sep 30, 2022
    Harvard Catalyst / NIH. - KL2/CMeRIT
    Evaluation of precision biomarkers and targeted therapies in patients with Ewing sarcoma
    Role: Trainee

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Nader JH, Neel DV, Shulman DS, Ma C, Bourgeois F, DuBois SG. Landscape of phase 1 clinical trials for minors with cancer in the United States. Pediatr Blood Cancer. 2020 Sep 04; e28694. PMID: 32886429.
    Citations:    Fields:    
  2. Lim M, Shulman DS, Roberts H, Li A, Clymer J, Bona K, Al-Sayegh H, Ma C, DuBois SG. Off-label prescribing of targeted anticancer therapy at a large pediatric cancer center. Cancer Med. 2020 Aug 04. PMID: 32750219.
    Citations: 1     Fields:    
  3. Liu KX, Collins NB, Greenzang KA, Furutani E, Campbell K, Groves A, Mullen EA, Shusterman S, Spidle J, Marcus KJ, Weil BR, Weldon CB, Frazier AL, Janeway KA, O'Neill AF, Mack JW, DuBois SG, Shulman DS. The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor. Pediatr Blood Cancer. 2020 Jul 19; e28559. PMID: 32686305.
    Citations:    Fields:    
  4. Neel DV, Shulman DS, Ma C, Bourgeois F, DuBois SG. Sponsorship of oncology clinical trials in the United States according to age of eligibility. Cancer Med. 2020 Jul; 9(13):4495-4500. PMID: 32351000.
    Citations: 1     Fields:    
  5. Kamihara J, Paulson V, Breen MA, Laetsch TW, Rakheja D, Shulman DS, Schoettler ML, Clinton CM, Ward A, Reidy D, Pinches RS, Weiser DA, Mullen EA, Schienda J, Meyers PA, DuBois SG, Nowak JA, Foulkes WD, Schultz KAP, Janeway KA, Vargas SO, Church AJ. DICER1-associated central nervous system sarcoma in children: comprehensive clinicopathologic and genetic analysis of a newly described rare tumor. Mod Pathol. 2020 10; 33(10):1910-1921. PMID: 32291395.
    Citations:    Fields:    
  6. Shulman DS, DuBois SG. The Evolving Diagnostic and Treatment Landscape of NTRK-Fusion-Driven Pediatric Cancers. Paediatr Drugs. 2020 Apr; 22(2):189-197. PMID: 31965543.
    Citations:    Fields:    Translation:Humans
  7. Shulman DS, Crompton BD. Using Liquid Biopsy in the Treatment of Patient with OS. Adv Exp Med Biol. 2020; 1257:95-105. PMID: 32483734.
    Citations:    Fields:    Translation:Humans
  8. Caruso J, Shulman DS, DuBois SG. Second malignancies in patients treated for Ewing sarcoma: A systematic review. Pediatr Blood Cancer. 2019 11; 66(11):e27938. PMID: 31347793.
    Citations: 1     Fields:    Translation:Humans
  9. Shulman DS, Klega K, Imamovic-Tuco A, Clapp A, Nag A, Thorner AR, Van Allen E, Ha G, Lessnick SL, Gorlick R, Janeway KA, Leavey PJ, Mascarenhas L, London WB, Vo KT, Stegmaier K, Hall D, Krailo MD, Barkauskas DA, DuBois SG, Crompton BD. Correction: Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. Br J Cancer. 2019 Apr; 120(8):869. PMID: 30880335.
    Citations:    Fields:    
  10. Neel DV, Shulman DS, DuBois SG. Timing of first-in-child trials of FDA-approved oncology drugs. Eur J Cancer. 2019 05; 112:49-56. PMID: 30928805.
    Citations: 5     Fields:    Translation:Humans
  11. Shulman DS, DuBois SG. Winning the RACE: Expanding pediatric cancer drug approvals. Pediatr Blood Cancer. 2019 08; 66(8):e27705. PMID: 30854771.
    Citations: 2     Fields:    Translation:Humans
  12. Ocwieja KE, Vargas SO, Elisofon SA, Shulman DS, Lee CK, Fawaz R, Collins N, Vakili K, Sharma TS. Pediatric post-transplant hepatic kaposi sarcoma due to donor-derived human herpesvirus 8. Pediatr Transplant. 2019 05; 23(3):e13384. PMID: 30843320.
    Citations:    Fields:    Translation:HumansCells
  13. Abbou SD, Shulman DS, DuBois SG, Crompton BD. Assessment of circulating tumor DNA in pediatric solid tumors: The promise of liquid biopsies. Pediatr Blood Cancer. 2019 05; 66(5):e27595. PMID: 30614191.
    Citations: 2     Fields:    Translation:Humans
  14. Shulman DS, Mehrotra P, Blonquist TM, Capraro A, Lehmann LE, Silverman LB, Surana NK, Place AE. A single institutional review of pediatric Bacillus spp. bloodstream infections demonstrates increased incidence among children with cancer. Pediatr Blood Cancer. 2019 04; 66(4):e27568. PMID: 30537106.
    Citations:    Fields:    Translation:HumansCells
  15. Shulman DS, Klega K, Imamovic-Tuco A, Clapp A, Nag A, Thorner AR, Van Allen E, Ha G, Lessnick SL, Gorlick R, Janeway KA, Leavey PJ, Mascarenhas L, London WB, Vo KT, Stegmaier K, Hall D, Krailo MD, Barkauskas DA, DuBois SG, Crompton BD. Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. Br J Cancer. 2018 08; 119(5):615-621. PMID: 30131550.
    Citations: 9     Fields:    Translation:Humans
  16. Campbell K, Shulman D, Janeway KA, DuBois SG. Comparison of Epidemiology, Clinical Features, and Outcomes of Patients with Reported Ewing Sarcoma and PNET over 40 Years Justifies Current WHO Classification and Treatment Approaches. Sarcoma. 2018; 2018:1712964. PMID: 30158829.
    Citations: 1     
  17. Shulman DS, Lee MA, Lehmann LE, Margossian SP. Outcomes Following Bone Marrow Transplantation in Children With Accelerated Phase or Blast Crisis Chronic Myelogenous Leukemia in the Era of Tyrosine Kinase Inhibitors. J Pediatr Hematol Oncol. 2016 11; 38(8):610-614. PMID: 27403776.
    Citations: 1     Fields:    Translation:Humans
  18. Mpunga T, Hedt-Gauthier BL, Tapela N, Nshimiyimana I, Muvugabigwi G, Pritchett N, Greenberg L, Benewe O, Shulman DS, Pepoon JR, Shulman LN, Milner DA. Implementation and Validation of Telepathology Triage at Cancer Referral Center in Rural Rwanda. J Glob Oncol. 2016 Apr; 2(2):76-82. PMID: 28717686.
    Citations: 7     Fields:    
  19. Shulman DS, London WB, Guo D, Duncan CN, Lehmann LE. Incidence and causes of hospital readmission in pediatric patients after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015 May; 21(5):913-9. PMID: 25667988.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  20. Mpunga T, Tapela N, Hedt-Gauthier BL, Milner D, Nshimiyimana I, Muvugabigwi G, Moore M, Shulman DS, Pepoon JR, Shulman LN. Diagnosis of cancer in rural Rwanda: early outcomes of a phased approach to implement anatomic pathology services in resource-limited settings. Am J Clin Pathol. 2014 Oct; 142(4):541-5. PMID: 25239422.
    Citations: 20     Fields:    Translation:Humans
  21. Filbin MG, Dabral SK, Pazyra-Murphy MF, Ramkissoon S, Kung AL, Pak E, Chung J, Theisen MA, Sun Y, Franchetti Y, Sun Y, Shulman DS, Redjal N, Tabak B, Beroukhim R, Wang Q, Zhao J, Dorsch M, Buonamici S, Ligon KL, Kelleher JF, Segal RA. Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities. Nat Med. 2013 Nov; 19(11):1518-23. PMID: 24076665.
    Citations: 59     Fields:    Translation:HumansAnimalsCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Shulman's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (95)
Explore
_
Co-Authors (44)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.